OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Cannavale on the Importance of Assessing Comorbidities and Remission Rates in Ovarian Cancer

September 13th 2024

Kimberly Cannavale, MPH, discusses the clinical implications of a study on the impact of pre-existing comorbidities on remission rates in ovarian cancer.

Dr Banerjee on the Impact of Dose Modification Studies in Multiple Myeloma

September 13th 2024

Rahul Banerjee, MD, FACP, discusses the clinical impact of dose modification studies on the treatment of patients with multiple myeloma.

Dr Nowakowski on Unmet Needs to be Addressed in R/R Follicular Lymphoma

September 13th 2024

Grzegorz S. Nowakowski, MD, discusses unmet needs that remain to be addressed in patients with relapsed/refractory follicular lymphoma.

Dr Price on the Potential Role for HPV-Targeted Immunotherapy Vaccines in HPV+ HNSCC

September 12th 2024

Katharine A. Price, MD, discusses the potential role for injectable HPV-targeted immunotherapy vaccines in HPV16-positive head and neck squamous cell carcinoma.

Dr Kim on the Safety of NT-17 Plus Pembrolizumab in Pretreated CRC and PDAC

September 11th 2024

Richard Kim, MD, discusses the safety of NT-17 and next steps for its evaluation in pretreated microsatellite stable CRC and PDAC.

Dr Danilov on the Current and Potential Use of Pirtobrutinib in CLL

September 11th 2024

Alexey Danilov, MD, PhD, discusses the utility of pirtobrutinib in patients with chronic lymphocytic leukemia.

Dr Danilov on Ongoing MCL Clinical Trials

September 11th 2024

Alexey Danilov, MD, PhD, discusses ongoing investigations taking place to improve the treatment of patients with mantle cell lymphoma.

Dr Eads on the Rationale for ECOG-ACRIN EA2174 in Esophageal/GEJ Adenocarcinoma

September 11th 2024

Jennifer R. Eads, MD, discusses the evaluation of the addition of nivolumab to neoadjuvant chemotherapy and radiation in esophageal/GEJ adenocarcinoma.

Dr Braun on the Role of Biomarkers in Guiding Adjuvant Treatment for RCC

September 11th 2024

David A. Braun, MD, PhD, discusses the role of biomarkers in guiding adjuvant treatment strategies for renal cell carcinoma.

Cannavale on the Effect of Comorbidity on Remission Rates in Epithelial Ovarian Cancer

September 11th 2024

Kimberly Cannavale, MPH, discusses the rationale for investigating the effect of pre-existing comorbidities on remission rates in ovarian cancer.

Dr Chalasani on the Potential Utility of Eftilagimod Alpha in HER2–/HER2-Low Breast Cancer

September 11th 2024

Pavani Chalasani, MD, MPH, discusses the potential clinical significance of the AIPAC-003 trial of eftilagimod alpha in HER2–/HER2-low breast cancer.

Dr Asare on the Elevated Risk of Secondary Leukemias in PARP Inhibitors in Gynecologic Cancers

September 10th 2024

Amma Asare, MD, PhD, discusses the elevated risk of therapy-related myeloid neoplasms or secondary leukemias in gynecologic cancers after a PARP inhibitor.

Dr D’Amico on the Nuances of a Low Gleason Score in Localized Prostate Cancer

September 10th 2024

Anthony V. D'Amico, MD, PhD, discusses Gleason score interpretation in the management of localized prostate cancer.

Dr Drakaki on the Investigation of Zanzalintinib in Advanced Non–Clear Cell RCC

September 10th 2024

Alexandra Drakaki, MD, PhD, discusses the potential role of zanzalintinib in advanced non–clear cell renal cell carcinoma.

Dr Nowakowski on Monitoring Epcoritamab-Associated ICANS and CRS in Follicular Lymphoma

September 10th 2024

Grzegorz S. Nowakowski, MD, discusses toxicity monitoring strategies for epcoritamab treatment in relapsed/refractory follicular lymphoma.

Dr Lonial on Characterizing Multiple Myeloma Subtypes in the CoMMpass Study

September 10th 2024

Sagar Lonial, MD, FACP, discusses unique subtypes of multiple myeloma identified through the CoMMpass study.

Dr Linscott on the Use of Urinary Cell-free Tumor DNA to Predict MRD in High-Risk NMIBC

September 10th 2024

Joshua Linscott, MD, PhD, discusses the use of utDNA to predict MRD prior to repeat TURBT in patients with high-risk non-muscle invasive bladder cancer.

Dr Yuan on Minimizing Lymph Node Surgical Intervention in Breast Cancer

September 10th 2024

Yuan Yuan, MD, PhD, discusses the potential shift towards minimizing surgical intervention for lymph node management in breast cancer.

Dr Heymach on Updated AEGEAN Data in Resectable NSCLC

September 9th 2024

John V. Heymach, MD, PhD, discusses updated outcomes from the AEGEAN trial of perioperative durvalumab vs placebo in resectable non–small cell lung cancer.

Dr Jhaveri on the Use of CDK4/6 Inhibitors Plus Endocrine Therapy in Breast Cancer

September 9th 2024